Mia T Minen1, Kathryn B Schaubhut2, Kaitlyn Morio2. 1. NYU Langone Health, Department of Neurology, 222 E 41st, Ninth floor, New York, NY, 10017. Electronic address: mia.minen@nyulangone.org. 2. Columbia University, Post-baccalaureate Premed Program, 408 Lewisohn Hall, 2970 Broadway, New York, NY 10027.
Abstract
BACKGROUND: Multiple Sclerosis (MS) and Migraine are comorbid neurologic conditions. Migraine prevalence is three times higher in the MS clinic population compared to the general population, and patients with MS and migraine are more symptomatic than patients with MS without migraine. OBJECTIVE: We sought to conduct a pilot feasibility and acceptability study of the RELAXaHEAD app in MS-Migraine patients and to assess whether there was any change in migraine disability and MS pain-related disability. METHODS: Randomized controlled study of patients with MS-migraine ages 18-80 years with 4+ headache days/ month who were willing to engage in smartphone based behavioral therapy. Half received the RELAXaHEAD app with progressive muscle relaxation (PMR) and the other half received the app without the PMR. Data was collected for 90 days on measures of recruitment, retention, engagement, and adherence to RELAXaHEAD. Preliminary data was also collected on migraine disability (MIDAS) and MS pain (PES). RESULTS:Sixty-two subjects with MS-migraine were enrolled in the study (34 in PMR arm, 28 in monitored usual care arm). On average, during the 90 days, participants played the PMR on average 1.8 times per week, and for 12.9 min on days it was played. Forty-one percent (14/34) of the participants played the PMR two or more times weekly on average. Data was entered into the daily diaries, on average, 49% (44/90) of the days. There were major challenges in reaching subjects in follow-up for the efficacy data, and there was no significant change in migraine disability (MIDAS) scores or MS Pain (PES) scores from baseline to the endpoints. During the six-month follow-up, most patients felt either positively or neutral about the relaxation therapy. CONCLUSION: There was interest in scalable accessible forms of behavioral therapy to treat migraine and MS-related pain in patients with MS and comorbid migraine. Similar to prior studies, a significant minority were willing to practice the PMR at least twice weekly. In the societal shift from telephone to more text and internet-based interactions, follow up was challenging, but those reached indicated that they appreciated the PMR and would recommend it to others. Future work should focus on engagement and efficacy.
RCT Entities:
BACKGROUND:Multiple Sclerosis (MS) and Migraine are comorbid neurologic conditions. Migraine prevalence is three times higher in the MS clinic population compared to the general population, and patients with MS and migraine are more symptomatic than patients with MS without migraine. OBJECTIVE: We sought to conduct a pilot feasibility and acceptability study of the RELAXaHEAD app in MS-Migrainepatients and to assess whether there was any change in migraine disability and MS pain-related disability. METHODS: Randomized controlled study of patients with MS-migraine ages 18-80 years with 4+ headache days/ month who were willing to engage in smartphone based behavioral therapy. Half received the RELAXaHEAD app with progressive muscle relaxation (PMR) and the other half received the app without the PMR. Data was collected for 90 days on measures of recruitment, retention, engagement, and adherence to RELAXaHEAD. Preliminary data was also collected on migraine disability (MIDAS) and MS pain (PES). RESULTS: Sixty-two subjects with MS-migraine were enrolled in the study (34 in PMR arm, 28 in monitored usual care arm). On average, during the 90 days, participants played the PMR on average 1.8 times per week, and for 12.9 min on days it was played. Forty-one percent (14/34) of the participants played the PMR two or more times weekly on average. Data was entered into the daily diaries, on average, 49% (44/90) of the days. There were major challenges in reaching subjects in follow-up for the efficacy data, and there was no significant change in migraine disability (MIDAS) scores or MS Pain (PES) scores from baseline to the endpoints. During the six-month follow-up, most patients felt either positively or neutral about the relaxation therapy. CONCLUSION: There was interest in scalable accessible forms of behavioral therapy to treat migraine and MS-related pain in patients with MS and comorbid migraine. Similar to prior studies, a significant minority were willing to practice the PMR at least twice weekly. In the societal shift from telephone to more text and internet-based interactions, follow up was challenging, but those reached indicated that they appreciated the PMR and would recommend it to others. Future work should focus on engagement and efficacy.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Mia T Minen; Kaitlyn Morio; Kathryn Berlin Schaubhut; Scott W Powers; Richard B Lipton; Elizabeth Seng Journal: Cephalalgia Date: 2019-12-23 Impact factor: 6.292
Authors: Rebecca Erwin Wells; Suzanne M Bertisch; Catherine Buettner; Russell S Phillips; Ellen P McCarthy Journal: Headache Date: 2011-06-07 Impact factor: 5.887
Authors: Robert W Motl; Ellen M Mowry; Dawn M Ehde; Nicholas G LaRocca; Kathy E Smith; Kathleen Costello; Lynne Shinto; Alexander V Ng; Amy B Sullivan; Barbara Giesser; Kevin K McCully; Bo Fernhall; Malachy Bishop; Matthew Plow; Patrizia Casaccia; Nancy D Chiaravalloti Journal: Mult Scler Date: 2017-01-12 Impact factor: 6.312
Authors: Dawn M Ehde; Kevin N Alschuler; Melissa A Day; Marcia A Ciol; Makena L Kaylor; Jennifer K Altman; Mark P Jensen Journal: Trials Date: 2019-12-27 Impact factor: 2.279
Authors: Mia T Minen; Neil A Busis; Steven Friedman; Maya Campbell; Ananya Sahu; Kazi Maisha; Quazi Hossain; Mia Soviero; Deepti Verma; Leslie Yao; Farng-Yang A Foo; Jaydeep M Bhatt; Laura J Balcer; Steven L Galetta; Sujata Thawani Journal: Digit Health Date: 2022-07-17
Authors: Robert Jakob; Samira Harperink; Aaron Maria Rudolf; Elgar Fleisch; Severin Haug; Jacqueline Louise Mair; Alicia Salamanca-Sanabria; Tobias Kowatsch Journal: J Med Internet Res Date: 2022-05-25 Impact factor: 7.076
Authors: Donna Langenbahn; Yuka Matsuzawa; Yuen Shan Christine Lee; Felicia Fraser; Donald B Penzien; Naomi M Simon; Richard B Lipton; Mia T Minen Journal: J Gen Intern Med Date: 2021-02-01 Impact factor: 5.128
Authors: William Bevens; Tracey Weiland; Kathleen Gray; George Jelinek; Sandra Neate; Steve Simpson-Yap Journal: J Med Internet Res Date: 2022-02-09 Impact factor: 5.428